FDA approves Jentadeuto

The U.S. Food and Drug Administration FDA) has approved Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. Jentadeuto XR can be used as an adjunct to diet and exercise to improve glycemic control in adults with T2D when treatment with both linagliptin and metformin is appropriate.

Read More

Panel recommends FDA approval of Xultophy

A U.S. advisory panel voted 16-0 in favour of the approval of iDegLira(Xultophy) by the Food and Drug Administration, for patients with type 2 diabetes. iDegLira combines Novo Nordisk's diabetes drug Tresiba, also known as insulin degludec, with its GLP-1 agonist Victoza, or liraglutide. iDeGlira would be appropriate for patients who were previously taking either insulin or a GLP-1 drug.

Meanwhile, an FDA advisory panel is scheduled to review Sanofi's application for the experimental diabetes drug iGlarLixi (lixisenatide/insulin glargine), which was awarded accelerated assessment earlier this year.

Read More